Vumerity Linked to Better Quality of Life Than Tecfidera in RRMS Trial 4.4 (9)
Vumerity (diroximel fumarate) is easier on the gastrointestinal tract than Tecfidera (dimethyl fumarate), and this translates into better quality of life for patients with relapsing-remitting multiple sclerosis (RRMS), a new analysis of EVOLVE-MS-2 trial data has found.
The study, “
Vumerity (previously BIIB098 and ALKS8700) is an oral delayed-release capsule marketed by Biogen that is approved for the treatment of relapsing forms of multiple sclerosis in adults. It has the same active metabolite (product resulting from the body’s chemical processes) as Tecfidera another approved oral medicine for relapsing forms of multiple sclerosis, also marketed by Biogen.
Thickness of Retina Layers May Predict MS Progression, Relapses
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
Gerald Orukwa: Setting records straight on J B C Udem s frivolous open letter to Gov Ugwuanyi over ESUTH
dailypost.ng - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypost.ng Daily Mail and Mail on Sunday newspapers.